Capital International Sarl’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Capital International Sarl’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-297,193	Closed	-$684K	–	247
2022 Q4	$684K	Sell	297,193 -7,389	-2%	-$22.6K	0.05%	195
2022 Q3	$981K	Buy	304,582 +2,400	+0.8%	+$7.81K	0.08%	187
2022 Q2	$1.66M	Buy	302,182 +74,033	+32%	+$230K	0.13%	161
2022 Q1	$532K	Buy	228,149 +8,508	+4%	+$29K	0.03%	242
2021 Q4	$1.33M	Buy	219,641 +60,150	+38%	+$578K	0.06%	214
2021 Q3	$2.21M	Buy	159,491 +15,436	+11%	+$182K	0.2%	127
2021 Q2	$1.87M	Buy	144,055 +10,779	+8%	+$144K	0.16%	139
2021 Q1	$2.05M	Buy	+133,276	New	+$3.15M	0.2%	125

Other funds holding GRCL

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Capital International Sarl's GRCL Position: Q1 2023 in Review

Capital International Sarl sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2023, closing a stake of 297,193 shares — an estimated $684K sold.

Capital International Sarl first reported a position in GRCL in Q1 2021 and held it in 8 quarters. The position peaked at $2.21M in Q3 2021. 33 funds tracked by Wall St. Rank hold GRCL as of Q1 2023.

Capital International Sarl reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2023 after selling out during the quarter.
Capital International Sarl sold 297,193 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2023, an estimated $684K.
Capital International Sarl first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 8 quarters.
Capital International Sarl's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $2.21M in Q3 2021.
33 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2023.

Based on Capital International Sarl's 13F filing for Q1 2023, filed 15 May 2023.